16.08.2010 • NewsHexionQ2 2010

Hexion Swings to Q2 Profit as Revenues Jump

Craig O. Morrison, Hexions chairman and chief executive
Craig O. Morrison, Hexion's chairman and chief executive

Privately owned Hexion Specialty Chemicals said it swung to a second-quarter profit versus a year-ago loss as sales volumes and prices rose. Net income was $52 million in the quarter versus a net loss of $56 million a year ago as revenues jumped to $1.3 billion from $956 million.

Lower expenses and an improved cost structure bolstered profit, partially offset by the impact from foreign currency, the company said. Sales volumes rose 30% from the prior-year period and 8 percent from the first quarter, aided by a recovery in Hexion's base epoxy business.

"Despite the ongoing volatility in various leading economic indicators, we remain optimistic that the recovery in volumes will continue in 2010," said Craig O. Morrison, Hexion's chairman and chief executive.

Hexion is owned by Apollo Management LP, a private equity firm that also owns the Harrah's casino chain and Norwegian Cruise Lines.

Company

Hexion Specialty Chemicals

Gennaerstr. 2-4
58642 Iserlohn
Germany

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.